Prestige Consumer Healthcare
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Prestige Consumer Healthcare (PBH) | 2.35B | 15.32 | 1.21 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 41.0% below Morningstar's fair value estimate.
Analyst note
Prestige Consumer Healthcare delivered second-quarter revenue growth of 23% this quarter (negative 2% organic), and adjusted EPS of 6%, both ahead of FactSet consensus. Management lowered full-year revenue and EPS guidance to midpoint figures of $1.29 billion and $4.52, respectively.
Why it matters: Prestige's reduced outlook and approximately 2% organic sales decline reflect continued production variability at Clear Eyes during the Pillar5 transition. While management previously anticipated improving stability in the second half of this year, it now expects a longer transition period, with the lowest Clear Eyes revenue in the third quarter. Despite Clear Eyes headwinds, the broader portfolio continues to perform well, with total revenue growth led by TheraTears, gastrointestinal products, and recent acquisitions. The quarter saw elevated demand for Dramamine and Fleet, which continue to benefit from GLP-1 utilization, while TheraTears also saw strong demand. This marked the first full quarter with meaningful contribution from the Breathe Right and LaCorium acquisitions, both of which we expect will be margin-accretive over time for Prestige. While any effect on margins was limited this quarter, we continue to view these acquisitions favorably as they expand Prestige's exposure to mature and predictable OTC end markets.
The bottom line: We maintain our fair value estimate of $70 per share for narrow-moat Prestige, as we believe that despite post-transition visibility being low, Prestige should enjoy a combination of operating leverage and margin expansion from its recent acquisitions and new manufacturing capabilities. Shares traded down over 15% Nov. 5, and we now see 50% upside from its current price. We view this market reaction as disproportionate to the severity of Clear Eyes' supply variability. While the Pillar5 transition phase appears more prolonged than initially expected, ClearEyes accounts for only a low-single-digit percentage of revenue.
We added Prestige to our Best Ideas List in November.
Fair value
We lower our fair value estimate to $70 per share from $77 for narrow-moat Prestige. Fiscal 2027 guidance includes 2% organic sales and EPS growth, both of which are lower than we had anticipated. Given the weak exit to the year and the firm's track record of lowering guidance throughout fiscal 2026, our estimates are on the lower end of the guidance range. Our forecast model has a five-year revenue CAGR of roughly 2% and a gradual year-over-year margin ramp-up. Our valuation reflects an EV/2027 EBITDA multiple of 11.
Prestige leads in many categories it serves, including motion sickness relief, vaginal antifungal remedies, and pharyngeal preparations. While these categories are small and niche, we think they will still grow in the low single digits over our forecast period, driven by industrywide trends, including an aging population, increasing focus on consumer health, and a premiumization of self-care. We also think that primarily playing in niche categories can somewhat mitigate pressure from private-label and larger OTC players, given their limited market size. We view the likelihood of a big manufacturer spending time and resources to launch a new product and displace Prestige’s products in these markets as low, given that they play in larger categories with a significantly larger addressable market.
In the long term, we forecast a low-single-digit top-line growth with a slight improvement in gross margin from supply chain efficiencies and manufacturing productivity improvements. We think the higher gross margin will be somewhat offset by elevated advertising and marketing spending, as we expect competition in consumer healthcare to intensify over the next five years due to large pure-play manufacturers such as Kenvue and Haleon entering the market in recent years.
Economic moat
We assign Prestige Consumer Healthcare a narrow moat rating because we believe the company’s strong brand reputation and pricing power (intangible assets) should continue to support economic profits for the next 10 years.
Over 80% of Prestige’s total sales are derived from its portfolio of 18 major brands. Many of Prestige’s brands play in niche categories—Boudreaux’s Butt Paste is baby ointment used to treat diaper rash, Debrox is an earwax removal drop, and Monistat is a vaginal anti-fungal cream. While we believe Prestige lags consumer health giants like Kenvue and Haleon in broad product channels such as analgesics, cough remedies, and oral care, we believe the company has successfully carved out a meaningful presence in smaller unique categories and garnered impressive market share. Prestige’s brands have also held their market leadership for over a decade, demonstrating stability of their market share. Lastly, Prestige’s brands do not have a meaningful competitor in most markets, and the rest of the space is shared among private-label brands that have failed to amass significant shares.
Many of Prestige’s brands come at a moderate to significant pricing premium when compared with its close competitors and that premium is magnified when compared with private label. But even at higher prices, we see that consumers continue to choose Prestige’s brands over its competitors’. One of the main reasons behind Prestige’s market leadership, in our opinion, is the significant brand power and customer loyalty that its brands have amassed with decades of history on the shelf and inside people’s homes. We also believe a number of Prestige’s brands are sought out in times of poor health, so the importance of brand familiarity and trust is heightened. And because Prestige’s brands are backed by years of scientific research, they benefit from recommendations of professionals across its mix of products. For example, Dramamine is the number one pharmacist-recommended brand for motion sickness, and Monistat is the number one gynecologist-recommended brand for vaginal anti-fungal remedies. The leading market shares in many of the categories it plays in, even at higher prices, illustrate Prestige’s strong brand reputation and high levels of consumer trust and loyalty.
To ensure its brand prowess and maintain its leading position, Prestige continues to innovate and launch new products to align with ever-changing consumer preferences. We estimate that the firm spends a low-single-digit percentage of sales on research and development and 15% on advertising and marketing, on par with its competitors Kenvue (4% and 10% of sales on R&D and A&M, respectively) and Procter & Gamble (3% and 11%, respectively). We believe Prestige can maintain its leading share position and entrenched standing with retailers through product innovation over the next 10 years thanks to its strong brand power and innovations.
Bull case
Prestige is well positioned to enjoy macro long-term trends, including aging population, rising awareness of self-care, and premiumization of consumer healthcare.
Prestige’s portfolio is filled with category-leading brands, and we believe it can increase its household penetration and bolster its brand equity through more research and innovation.
By focusing on small and niche markets, we believe Prestige is more insulated from private-label entry compared with products that play in larger categories.
Bear case
Emerging large players in the consumer healthcare space, including Haleon and Kenvue, have the resources to expand their portfolios and displace smaller brands that Prestige owns.
Prestige spends less as a percentage of sales on research and development compared with larger competitors in the space, which could make the company susceptible to fall out of ever-changing consumer preferences.
Mismanagement in production could lead to product recalls and result in large settlement fees, putting pressure on Prestige’s bottom line.
By Keonhee Kim
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Prestige Consumer Healthcare discussion 0 comments